Literature DB >> 11071887

Processing of beta-secretase by furin and other members of the proprotein convertase family.

J W Creemers1, D Ines Dominguez, E Plets, L Serneels, N A Taylor, G Multhaup, K Craessaerts, W Annaert, B De Strooper.   

Abstract

The amyloid peptide is the main constituent of the amyloid plaques in brain of Alzheimer's disease patients. This peptide is generated from the amyloid precursor protein by two consecutive cleavages. Cleavage at the N terminus is performed by the recently discovered beta-secretase (Bace). This aspartyl protease contains a propeptide that has to be removed to obtain mature Bace. Furin and other members of the furin family of prohormone convertases are involved in this process. Surprisingly, beta-secretase activity, neither at the classical Asp(1) position nor at the Glu(11) position of amyloid precursor protein, seems to be controlled by this maturation step. Furthermore, we show that Glu(11) cleavage is a function of the expression level of Bace, that it depends on the membrane anchorage of Bace, and that Asp(1) cleavage can be followed by Glu(11) cleavage. Our data suggest that pro-Bace could be active as a beta-secretase in the early biosynthetic compartments of the cell and could be involved in the generation of the intracellular pool of the amyloid peptide. We conclude that modulation of the conversion of pro-Bace to mature Bace is not a relevant drug target to treat Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071887     DOI: 10.1074/jbc.M006947200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

Review 3.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

4.  Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Authors:  Lujia Zhou; Lucia Chávez-Gutiérrez; Katrijn Bockstael; Ragna Sannerud; Wim Annaert; Patrick C May; Eric Karran; Bart De Strooper
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 5.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

Review 6.  Processing of peptide and hormone precursors at the dibasic cleavage sites.

Authors:  Mohamed Rholam; Christine Fahy
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 7.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

8.  Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.

Authors:  Kulandaivelu S Vetrivel; Xavier Meckler; Ying Chen; Phuong D Nguyen; Nabil G Seidah; Robert Vassar; Philip C Wong; Masaki Fukata; Maria Z Kounnas; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

9.  Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors.

Authors:  Yu-Chen Yen; Annalissa M Kammeyer; Katherine C Jensen; Jagannadharao Tirlangi; Arun K Ghosh; Andrew D Mesecar
Journal:  Biochemistry       Date:  2019-10-22       Impact factor: 3.162

10.  Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease.

Authors:  T Lashley; T Revesz; G Plant; R Bandopadhyay; A J Lees; B Frangione; N W Wood; R de Silva; J Ghiso; A Rostagno; J L Holton
Journal:  Neuropathol Appl Neurobiol       Date:  2008-02-13       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.